Rossella Sasanelli, Angelina Boccarelli, Domenico Giordano, Mariarita Laforgia, Fabio Arnesano, Giovanni Natile, Cosimo Cardellicchio, Maria A M Capozzi, Mauro Coluccia
Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Bari, 70124 Bari, Italy.
Journal of medicinal chemistry 2007 Jul 26Platinum complexes able to inhibit matrix metalloproteinases (MMPs) through a noncompetitive mechanism are reported for the first time in this study. [PtCl2(SMP)] and [Pt(dimethylmalonato)(SMP)], characterized by the bisphosphonate-analogue ligand diethyl[(methylsulfinyl)methyl]phosphonate (SMP), are slight inhibitors of MMP-2 (IC50 = 258 +/- 38 and 123 +/- 14 microM, respectively) but markedly inhibit MMP-9 (IC50 = 35.5 +/- 6 and 17 +/- 4 microM), MMP-3 (IC50 = 5.3 +/- 2.9 and 4.4 +/- 2.2 microM), and MMP-12 (IC50 = 10.8 +/- 3 and 6.2 +/- 1.8 microM). In contrast, cisplatin, carboplatin, and the SMP ligand are inactive, and the bisphosphonate clodronate shows a broad-spectrum inhibitory activity in the high micromolar range (mean IC50 > 200 microM). These results, along with mechanistic investigations (DNA interaction and tumor cell growth inhibition), demonstrate that ligand modifications of platinum compounds can be exploited to target also biological substrates distinct from DNA.
Rossella Sasanelli, Angelina Boccarelli, Domenico Giordano, Mariarita Laforgia, Fabio Arnesano, Giovanni Natile, Cosimo Cardellicchio, Maria A M Capozzi, Mauro Coluccia. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. Journal of medicinal chemistry. 2007 Jul 26;50(15):3434-41
Mesh Tags
Substances
PMID: 17583333
View Full Text